Skip to main content
Top
Published in: Clinical Pharmacokinetics 1/2001

01-12-2001 | Original Research Article

Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers

Authors: Dr Heino Stass, Richard Sachse

Published in: Clinical Pharmacokinetics | Special Issue 1/2001

Login to get access

Abstract

Objective

To investigate the effect of oral probenecid on the pharmacokinetics of oral moxifloxacin in healthy adult male volunteers.

Design and setting

This was a nonblinded, randomised, 2-way crossover study.

Patients and participants

12 male Caucasian volunteers (mean age 33.7 years) participated in the study.

Methods

A single oral dose of moxifloxacin 400mg was administered after an overnight fast with or without a 2-day course of probenecid 500mg twice daily starting at 1 hour before the moxifloxacin dose. There was a washout phase of at least 1 week between the 2 treatments. Samples of plasma and urine were taken according to predefined sampling schedules and the concentrations of moxifloxacin were determined with a validated high performance liquid chromatography assay with fluorescence detection. Noncompartmental pharmacokinetic data were calculated.

Results

Pharmacokinetic results with and without probenecid were virtually identical except for a slight delay in absorption with probenecid, indicated by a very slightly increased time to maximum concentration and a decreased maximum concentration (approximately 10%), which was not clinically relevant. Probenecid had no significant influence on the renal elimination of moxifloxacin, suggesting urinary excretion by glomerular filtration and partial tubular reabsorption. Safety and tolerability were good, with no clinically relevant drug-related adverse events or changes in laboratory parameters.

Conclusion

Dosage adjustments for moxifloxacin are not necessary when it is administered together with probenecid.
Literature
1.
go back to reference Balfour JAB, Wiseman LR. Moxifloxacin. Drags 1999; 57: 365–73 Balfour JAB, Wiseman LR. Moxifloxacin. Drags 1999; 57: 365–73
2.
go back to reference MacGowan AP. Moxifloxacin (BAY 12-8039): a new methoxy quinolone antibacterial. Exp Opin Invest Drugs 1999; 8: 181–99CrossRef MacGowan AP. Moxifloxacin (BAY 12-8039): a new methoxy quinolone antibacterial. Exp Opin Invest Drugs 1999; 8: 181–99CrossRef
3.
go back to reference Wise R. Areview of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365–87CrossRef Wise R. Areview of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365–87CrossRef
4.
go back to reference Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42(8): 2060–5CrossRef Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42(8): 2060–5CrossRef
5.
go back to reference Stass HH, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83–9CrossRef Stass HH, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83–9CrossRef
6.
go back to reference Ballow C, Lettieri J, Agarwal V, et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513–22CrossRef Ballow C, Lettieri J, Agarwal V, et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513–22CrossRef
7.
go back to reference Stass H, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine [abstract no. 3357]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108 Stass H, Ochmann K. Study to evaluate the interaction between BAY 12-8039 and ranitidine [abstract no. 3357]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108
8.
go back to reference Stass H, Kubitza D, Schwietert HR, et al. BAY 12-8039 does not interact with theophylline [abstract no. 3356 ]. 20th International Congress on Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108 Stass H, Kubitza D, Schwietert HR, et al. BAY 12-8039 does not interact with theophylline [abstract no. 3356 ]. 20th International Congress on Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108
9.
go back to reference Stass HH, Müller F, Hundt HKL, et al. Study of the influence of once-daily dosing of 400 mg moxifloxacin on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers [abstract no. A13]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, California: 4 Stass HH, Müller F, Hundt HKL, et al. Study of the influence of once-daily dosing of 400 mg moxifloxacin on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers [abstract no. A13]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, California: 4
10.
go back to reference Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Practice 2000; 3: 15–23 Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Practice 2000; 3: 15–23
11.
go back to reference Stass H, Böttcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 and antacids [abstract no. 3358]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108 Stass H, Böttcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 and antacids [abstract no. 3358]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108
12.
go back to reference Siefert HM, Domdey-Bette A, Henninger K, et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 Suppl B: 69–76CrossRef Siefert HM, Domdey-Bette A, Henninger K, et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 Suppl B: 69–76CrossRef
13.
go back to reference Stass H, Dalhoff A. Determination of BAY-12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74CrossRef Stass H, Dalhoff A. Determination of BAY-12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74CrossRef
14.
go back to reference Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York; Marcel Dekker Inc., 1982 Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York; Marcel Dekker Inc., 1982
15.
go back to reference Beyer KH, Russo HF, Tillson EK, et al. Benemid, p-(di-n-propylsulfamyl)-benzoic acid: its renal affinity and its elimination. Am J Physiol 1951; 166: 625–40CrossRef Beyer KH, Russo HF, Tillson EK, et al. Benemid, p-(di-n-propylsulfamyl)-benzoic acid: its renal affinity and its elimination. Am J Physiol 1951; 166: 625–40CrossRef
16.
go back to reference Drummer OH, Thompson J, Hooper R, et al. Effect of probenecid on the disposition of Captopril and Captopril dimer in the rat. Biochem Pharmacol 1985; 34: 3347–51CrossRef Drummer OH, Thompson J, Hooper R, et al. Effect of probenecid on the disposition of Captopril and Captopril dimer in the rat. Biochem Pharmacol 1985; 34: 3347–51CrossRef
17.
go back to reference Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 Suppl. A: 311–20CrossRef Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 Suppl. A: 311–20CrossRef
18.
go back to reference Chatton JY, Odone M, Besseghir K, et al. Renal secretion of 3′-azido-3′-deoxythymidine by the rat. J Pharmacol Exp Ther 1990; 255: 140–5PubMed Chatton JY, Odone M, Besseghir K, et al. Renal secretion of 3′-azido-3′-deoxythymidine by the rat. J Pharmacol Exp Ther 1990; 255: 140–5PubMed
19.
go back to reference Nadai M, Apichartpichean R, Hasegawa T, et al. Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. J Pharm Sci 1992; 81: 1024–7CrossRef Nadai M, Apichartpichean R, Hasegawa T, et al. Pharmacokinetics and the effect of probenecid on the renal excretion mechanism of diprophylline. J Pharm Sci 1992; 81: 1024–7CrossRef
20.
go back to reference Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101–19CrossRef Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101–19CrossRef
21.
go back to reference Foote EF, Halstenson CE. Effects of probenecid and Cimetidine on renal disposition of Ofloxacin in rats. Antimicrob Agents Chemother 1998; 42: 456–8PubMedPubMedCentral Foote EF, Halstenson CE. Effects of probenecid and Cimetidine on renal disposition of Ofloxacin in rats. Antimicrob Agents Chemother 1998; 42: 456–8PubMedPubMedCentral
22.
go back to reference Jaehde U, Sörgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of Ciprofloxacin in humans. Clin Pharmacol Ther 1995; 58: 532–41CrossRef Jaehde U, Sörgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of Ciprofloxacin in humans. Clin Pharmacol Ther 1995; 58: 532–41CrossRef
23.
go back to reference Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39: 2635–40CrossRef Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39: 2635–40CrossRef
24.
go back to reference Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharm Ther Tox 1991; 29(8): 323–8 Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharm Ther Tox 1991; 29(8): 323–8
25.
go back to reference Stass HH, Halabi A, Delesen H. No dose adjustment is needed for patients with renal impairment receiving oral moxifloxacin [abstract A14]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, California: 5 Stass HH, Halabi A, Delesen H. No dose adjustment is needed for patients with renal impairment receiving oral moxifloxacin [abstract A14]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, California: 5
Metadata
Title
Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers
Authors
Dr Heino Stass
Richard Sachse
Publication date
01-12-2001
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue Special Issue 1/2001
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200140001-00010

Other articles of this Special Issue 1/2001

Clinical Pharmacokinetics 1/2001 Go to the issue